Abstract:Multi drug resistance (MDR) in breast carcinoma still poses a significant impairment to successful chemotherapy. As the arsenal of anticancer agents increases with improved preclinical methods, the growth of therapeutic drug combinations is now unprecedented. The malignancies addressed by mono drugs often fail to limit cancer progression, resulting in resistant cancer, thereby offering combinatorial therapies a terrific edge over monodrug regimes. However, the selection of drug combinations required enough preliminary evidence for their synergistic effect. The fundamental mechanisms of MDR to chemotherapeutics are associated with the overexpression of membrane efflux pumps, alternations in drug targets, and increased drug metabolism. Unfortunately, it is very difficult for drugs to overcome resistance produced on their own or by another different drug action. In this context, herein, we report a simple delivery system for coencapsulation and intracellular codelivery of dual-drug thymoquinone (TQ) and doxorubicin (DOX) to resensitize DOX-resistant MDA MB231 cell line (231 R). The 231 R cell line developed in our lab showed an enhanced expression of the ATP-binding cassette (ABC) transporters P-gp1/MDR-1 and a declined miR-298 expression. The present delivery system is based on amine-functionalized mesoporous silica nanoparticles (MSNs), in which the side chain amine functional group was used to react with the carbonyl group of TQ, which acts as a pro-drug system (TQ-MSN) to release TQ and DOX simultaneously. DOX was encapsulated later into the above TQ-MSN by a simple diffusion method. The drugs containing MSNs were further coated with a hyaluronic acid-conjugated PEG-PLGA polymer (HA@TQ-DOX-MSN). This simple nanostrategy interferes with the MDR-1/miR-298 cross-talk, thereby allowing a significant reduction in drug efflux from the cell and highlighting a promising nanotechnology-based combinatorial delivery approach in managing breast cancer chemoresistance.

Codelivery of Thioridazine and Doxorubicin Using Nanoparticles for Effective Breast Cancer Therapy.

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Synergistic Breast Tumor Cell Killing Achieved by Intracellular Co-Delivery of Doxorubicin and Disulfiram Via Core-Shell-corona Nanoparticles

Ratiometric Co-Delivery of Doxorubicin and Docetaxel by Covalently Conjugating with Mpeg-Poly(β-malic Acid) for Enhanced Synergistic Breast Tumor Therapy

Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Dual-responsive Nanoparticles for Enhanced Drug Delivery in Breast Cancer Chemotherapy

Co-delivery Honokiol and Doxorubicin in MPEG-PLA Nanoparticles.

Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma

Co-delivery of Doxorubicin and Arsenite with Reduction and Ph Dual-Sensitive Vesicle for Synergistic Cancer Therapy

PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy

High loading of hydrophilic/hydrophobic doxorubicin into polyphosphazene polymersome for breast cancer therapy.

Codelivery of Doxorubicin/PI3K Inhibitor Nanomicelle Linked with Phenylboronic Acid for Enhanced Cytotoxicity to Pancreatic Cancer

Co-delivery of Doxorubicin Encapsulated PLGA Nanoparticles and Bcl-xL shRNA Using Alkyl-Modified PEI into Breast Cancer Cells

Fabrication of Poly Dopamine@poly (Lactic Acid-Co-Glycolic Acid) Nanohybrids for Cancer Therapy via a Triple Collaboration Strategy

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Doxorubicin-Loaded Carborane-Conjugated Polymeric Nanoparticles As Delivery System for Combination Cancer Therapy

Biodegradable and Amphiphilic Block Copolymer-Doxorubicin Conjugate As Polymeric Nanoscale Drug Delivery Vehicle for Breast Cancer Therapy.

Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk

Doxorubicin/cisplatin Co-Loaded Hyaluronic Acid/chitosan-Based Nanoparticles for in Vitro Synergistic Combination Chemotherapy of Breast Cancer

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy